Author/Authors :
Sanei، Hamid نويسنده Department of Internal Medicine , , Hajiannejad، Alireza نويسنده Resident, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran , , Sajjadieh-Kajouei، Amirreza نويسنده Cardiologist, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran , , Nazemzadeh، Neda نويسنده Internist, Department of Nephrology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , , Alizadeh، Nehzat نويسنده Resident, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , , Bidram، Peyman نويسنده Resident, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran , , Pourheidar، Behrouz نويسنده Resident, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran ,
Abstract :
BACKGROUND: Statins are shown effective by some studies in preventing contrast-induced
nephropathy (CIN). We evaluated the effectiveness of atorvastatin in the prevention of CIN in
computed tomography angiography (CTA) candidates.
METHODS: This study was conducted on patients referring for elective CTA with normal renal
function. Patients received atorvastatin (80 mg/day) or placebo from 24 h before to 48 h after
administration of the contrast material. Serum creatinine was measured before and 48 h after
contrast material injection. CIN was defined as an increase in serum creatinine level of ? 0.5
mg/dl or ? 25% of the baseline creatinine.
RESULTS: A total of 236 patients completed the study; 115 atorvastatin, 121 placebo, mean
age = 58.40 ± 9.80 year, 68.6% male. Serum creatinine increased after contrast material
injection in both the atorvastatin (1.00 ± 0.16-1.02 ± 0.15 mg/dl, P = 0.017) and placebo groups
(1.03 ± 0.17-1.08 ± 0.18 mg/dl, P < 0.001). Controlling for age, gender, comorbidities, drug
history, and baseline serum creatinine level, patients who received atorvastatin experienced less
increase in serum creatinine after contrast material injection (beta = 0.127, P = 0.034).
However, there was no difference between the atorvastatin and placebo groups in the incidence
of CIN (4.3 vs. 5.0%, P = 0.535).
CONCLUSION: In patients undergoing CTA, a short-term treatment with high dose atorvastatin
is effective in preventing contrast-induced renal dysfunction, in terms of less increase in serum
creatinine level after contrast material injection. Further trials including larger sample of
patients and longer follow-ups are warranted.
